Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.67 |
| ▸ | PTGER1 | P34995 | 14/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333284 | 0.84 | PTGDR2 (0.65) | MRGPRX4PTGER1 | |
| SCHEMBL22480554 | 0.80 | MRGPRX4 (1.00) | MRGPRX4SLC6A4 | |
| SCHEMBL8323718 | 0.80 | MRGPRX4 (0.53) | MRGPRX4PTGER1 | |
| SCHEMBL4170223 | 0.80 | PTGER1 (0.65) | PTGER1 | |
| SCHEMBL4720248 | 0.79 | PTGER1 (0.52) | MRGPRX4PTGER1SLC6A4 | |
| SCHEMBL5400480 | 0.78 | MRGPRX4 (0.51) | MRGPRX4PTGER1SLC6A4 | |
| SCHEMBL18614932 | 0.78 | MRGPRX4 (0.76) | MRGPRX4SLC6A4 | |
| SCHEMBL4773018 | 0.77 | PTGER1 (0.64) | MRGPRX4PTGER1 | |
| SCHEMBL8675658 | 0.76 | HTR1A (0.49) | MRGPRX4PTGER1 | |
| SCHEMBL30557975 | 0.76 | PTGER1 (0.54) | PTGER1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394986-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB | 2011-11-17 | — | — | US | disclosed |
| US-8003703-B2 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1660431-A2 | PHENOXYACETIC ACID DERIVATIVES | Astrazeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005018529-A2 | PHENOXIACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | MRGPRX4 49/4885PTGER1 60/4885SLC6A4 2808/4885 |
| US-20110281898-A1 | PHENOXIACETIC ACID DERIVATIVES | HIF1A, HPD, HIF1AN | MRGPRX4 1800/4885PTGER1 455/4885SLC6A4 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.